Grandone E, Bitsadze V, Khizroeva J, Chinni E, Mastroianno M, Nappi L
J Clin Med. 2025; 14(4).
PMID: 40004587
PMC: 11856335.
DOI: 10.3390/jcm14041053.
Wang Y, Yi Y, Guu H, Chen Y, Kung H, Chang J
Front Endocrinol (Lausanne). 2024; 15:1461317.
PMID: 39229374
PMC: 11368714.
DOI: 10.3389/fendo.2024.1461317.
Khattab N, Razzouk R, Tanios B, Nahouli L, Bou Khalil P, El Khoury N
Cureus. 2024; 16(9):e68467.
PMID: 39224493
PMC: 11368172.
DOI: 10.7759/cureus.68467.
Zhou J, Chen Y, Bai L, Zhou W, Yang H, Chen Y
J Ovarian Res. 2024; 17(1):98.
PMID: 38725001
PMC: 11084021.
DOI: 10.1186/s13048-024-01406-3.
Hatata M, Soliman D, Hosni K
Qatar Med J. 2023; 2023(3):22.
PMID: 38089671
PMC: 10714016.
DOI: 10.5339/qmj.2023.22.
Assisted reproductive technology: what are the cardiovascular risks for women?.
Guan C, Rodriguez C, Elder-Odame P, Minhas A, Zahid S, Baker V
Expert Rev Cardiovasc Ther. 2023; 21(10):663-673.
PMID: 37779500
PMC: 10615881.
DOI: 10.1080/14779072.2023.2266355.
Severe Ovarian Hyperstimulation Syndrome in the Setting of In Vitro Fertilization Treatment.
Diaz Ayllon H, Hernandez O, Nagi T, Cespedes C
Cureus. 2023; 15(6):e39939.
PMID: 37409193
PMC: 10319358.
DOI: 10.7759/cureus.39939.
Egg donor self-reports of ovarian hyperstimulation syndrome: severity by trigger type, oocytes retrieved, and prior history.
Tober D, Richter K, Zubizarreta D, Daneshmand S
J Assist Reprod Genet. 2023; 40(6):1291-1304.
PMID: 37347350
PMC: 10310641.
DOI: 10.1007/s10815-023-02855-3.
Global Transcriptional Profiling of Granulosa Cells from Polycystic Ovary Syndrome Patients: Comparative Analyses of Patients with or without History of Ovarian Hyperstimulation Syndrome Reveals Distinct Biomarkers and Pathways.
Daghestani M, Alqahtani H, AlBakheet A, Al Deery M, Awartani K, Daghestani M
J Clin Med. 2022; 11(23).
PMID: 36498516
PMC: 9740016.
DOI: 10.3390/jcm11236941.
Ovarian Hyperstimulation Syndrome: A Simulation Case for Emergency Medicine Residents.
Wittels K, Mayes K, Eyre A
MedEdPORTAL. 2022; 18:11271.
PMID: 36157358
PMC: 9445087.
DOI: 10.15766/mep_2374-8265.11271.
Follicular fluid PlGF and IVF/ICSI outcomes among PCOS and normo-ovulatory women using different controlled hyperstimulation protocols: A prospective case-control study.
Kadoura S, Alhalabi M, Nattouf A
Ann Med Surg (Lond). 2022; 79:104096.
PMID: 35860057
PMC: 9289487.
DOI: 10.1016/j.amsu.2022.104096.
Risk Factors and Methods for Predicting Ovarian Hyperstimulation Syndrome (OHSS) in the in vitro Fertilization.
Pakhomov S, Orlova V, Verzilina I, Sukhih N, Nagorniy A, Matrosova A
Arch Razi Inst. 2022; 76(5):1461-1468.
PMID: 35355759
PMC: 8934082.
DOI: 10.22092/ari.2021.355581.1700.
Dual trigger protocol is an effective in vitro fertilization strategy in both normal and high responders without compromising pregnancy outcomes in fresh cycles.
Chung R, Mancuso A, Summers K, Sparks A, Duran H, Mejia R
F S Rep. 2021; 2(3):314-319.
PMID: 34553157
PMC: 8441566.
DOI: 10.1016/j.xfre.2021.05.008.
Anti-Müllerian Hormone Predictive Levels to Determine The Likelihood of Ovarian Hyper-Response in Infertile Women with Polycystic Ovarian Morphology.
Akbari Sene A, Ashrafi M, Alaghmand-Fard N, Mohammadi N, Mortezapour Alisaraie M, Alizadeh A
Int J Fertil Steril. 2021; 15(2):115-122.
PMID: 33687164
PMC: 8052798.
DOI: 10.22074/IJFS.2020.134614.
Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles.
Kitasaka H, Tokoro M, Kojima M, Fukunaga N, Asada Y
Reprod Med Biol. 2021; 20(1):96-107.
PMID: 33488289
PMC: 7812458.
DOI: 10.1002/rmb2.12359.
Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients.
Christ J, Herndon C, Yu B
J Assist Reprod Genet. 2021; 38(3):751-756.
PMID: 33471229
PMC: 7910346.
DOI: 10.1007/s10815-020-02051-7.
A decision-making algorithm for performing or cancelling embryo transfer in patients at high risk for ovarian hyperstimulation syndrome after triggering final oocyte maturation with hCG.
Lainas G, Lainas T, Sfontouris I, Venetis C, Kyprianou M, Petsas G
Hum Reprod Open. 2020; 2020(3):hoaa013.
PMID: 32529046
PMC: 7275634.
DOI: 10.1093/hropen/hoaa013.
Comparison Between PPOS and GnRHa-Long Protocol in Clinical Outcome with the First IVF/ICSI Cycle: A Randomized Clinical Trial.
Xi Q, Tao Y, Qiu M, Wang Y, Kuang Y
Clin Epidemiol. 2020; 12:261-272.
PMID: 32184672
PMC: 7060798.
DOI: 10.2147/CLEP.S226414.
Concentration of soluble urokinase plasminogen activator receptor (suPAR) in the pre-ovulatory follicular fluid is associated with development of ovarian hyperstimulation syndrome during ovarian stimulation.
Grynnerup A, Toftager M, Zedeler A, Bogstad J, Praetorius L, Grondahl M
J Assist Reprod Genet. 2018; 35(12):2187-2193.
PMID: 30232642
PMC: 6289922.
DOI: 10.1007/s10815-018-1314-2.
Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.
Namavar Jahromi MD B, Parsanezhad MD M, Shomali MD Z, Bakhshai MD P, Alborzi MD M, Moin Vaziri MD PhD N
Iran J Med Sci. 2018; 43(3):248-260.
PMID: 29892142
PMC: 5993897.
